Qube Research & Technologies (QRT)
NRIX icon

Qube Research & Technologies (QRT)’s Nurix Therapeutics NRIX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.52M Buy
485,212
+459,223
+1,767% +$7.61M 0.01% 1455
2025
Q4 		$493K Sell
25,989
-690,546
-96% -$9.92M ﹤0.01% 2812
2025
Q3 		$6.62M Buy
716,535
+359,793
+101% +$3.74M 0.01% 1581
2025
Q2 		$4.06M Buy
356,742
+61,995
+21% +$670K ﹤0.01% 1832
2025
Q1 		$3.5M Sell
294,747
-58,724
-17% -$982K ﹤0.01% 1719
2024
Q4 		$6.66M Buy
353,471
+138,743
+65% +$3.18M 0.01% 1335
2024
Q3 		$4.82M Buy
214,728
+119,304
+125% +$2.7M 0.01% 1405
2024
Q2 		$1.99M Buy
+95,424
New +$1.49M ﹤0.01% 1628
2023
Q1 		– Sell
-11,179
Closed -$123K – 2870
2022
Q4 		$123K Buy
+11,179
New +$135K ﹤0.01% 1951
2022
Q2 		– Sell
-33,003
Closed -$462K – 2930
2022
Q1 		$462K Buy
+33,003
New +$586K ﹤0.01% 1570

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NRIX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Nurix Therapeutics (NRIX) stake by 1,767% in Q1 2026, buying an estimated $7.61M and bringing the position to 485,212 shares worth $7.52M. The position accounts for 0.01% of the portfolio, ranked #1455.

Qube Research & Technologies (QRT) first reported a position in NRIX in Q1 2022 and has held it in 10 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Qube Research & Technologies (QRT) held 485,212 shares of Nurix Therapeutics worth $7.52M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 459,223 Nurix Therapeutics shares in Q1 2026, an estimated $7.61M.
  • Nurix Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #1455 holding.
  • Qube Research & Technologies (QRT) first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.